Establishing a Long Island Bioscience Hub

 描述（由申请人提供）：在学术界存在一个特殊的机会，通过开发，翻译和商业化的基本发现，从我们的学术机构的生物医学研究企业产生，以促进人类健康。不幸的是，创新的识别、转化、开发和最终商业化的过程仍然远远没有达到最佳状态，使该地区的智力资本无法充分实现经济和社会效益。为了满足这一需求，我们建议建立一个由斯托尼布鲁克大学（SBU）、冷泉港实验室（CSHL）和布鲁克海文国家实验室（BNL）组成的区域伙伴关系。这些机构在生物科学创新方面的能力得到了证明，这些创新推动了生物医学科学的发展，并通过FDA批准的治疗方法，包括ReoPro（r）、SAFHS（r）、Xiaflex（r）、Periostat（r）和Oracea（r），新的医疗设备，包括3 D虚拟结肠镜检查和LivMD（r），以及新公司的成立，包括新英格兰BioLabs、OSI Pharmaceuticals、Collagenex、Pharmacopeia，Exogen和Set Point Medical。通过四个具体目标，这个国家（SBU），私人（CSHL）和联邦（BNL）的伙伴关系将建立在转化生物医学研究和商业化的现有优势，以：A）开发基础设施和实施系统，B）从我们的基础生物医学研究企业中增加新的医疗保健创新的产量，C）推动扎根于该地区的新生物技术，制药和医疗器械公司的形成，D）培养下一代生物企业家领导这些企业。总的来说，这些目标将为一个充满活力的生物科学产业集群奠定基础，这将促进一个不断扩大的长岛生物科学中心（LIBH）。

 DESCRIPTION (provided by applicant): An exceptional opportunity exists within the academic sector to promote human health through the development, translation and commercialization of basic discoveries which arise from the biomedical research enterprise of our academic institutions. Unfortunately, the process by which innovations are identified, translated, developed, and ultimately commercialized is still far from optimal, leaving the full economic and societal benefit from the region's intellectual capital unrealized. To address this need, we propose to form a regional partnership comprised of Stony Brook University (SBU), Cold Spring Harbor Laboratory (CSHL) and Brookhaven National Laboratory (BNL). These institutions have a demonstrated capacity for bioscience innovation that has advanced the course of biomedical science and contributed to improved healthcare through FDA approved therapies including ReoPro(r), SAFHS(r), Xiaflex(r), Periostat(r) and Oracea(r), new medical devices including 3D- virtual colonoscopy and LivMD(r), and new company formation including New England BioLabs, OSI Pharmaceuticals, Collagenex, Pharmacopeia, Exogen and Set Point Medical. Through four specific aims, this State (SBU), Private (CSHL) and Federal (BNL) partnership will build upon existing strengths in translational biomedical research and commercialization to: A) Develop an infrastructure and implementation system, B) Increase the yield of new healthcare innovations from within our basic biomedical research enterprise, C) Fuel new biotech, pharma and medical device company formation rooted within the region, and D) Train next generation bio-entrepreneurs to lead these ventures. In aggregate, these objectives will provide the foundation for a vibrant bioscience industry cluster that will foster an ever-expanding Long Island Bioscience Hub (LIBH).